Oral antibiotic prophylaxis versus immunoglobulin replacement for secondary hypogammaglobulinemia in hematological malignancy

Phase 2, randomised, open-label trial of trimethoprim + sulfamethoxazole, doxycycline and polyvalent human immunoglobulin in hypogammaglobulinemia and hematopoietic malignancies (2 arms), sponsored by Monash University. Primary endpoint: Proportion of patients alive who remain on assigned treatment arm at 12 months. Started Jun 2017; status: recruiting.